“…ActRI is the interacting protein of ActRIIB binding to myostatin ( Hata & Chen, 2016 ), and its lower expression was observed with interference of Es-ActRIIB in this study; the expressions of downstream transcription factors SMAD3 and SMAD4 were not influenced, the reason probably was that SMAD s, as core and versatile cytokines, are active in the TGF-β pathway, including the signal transduction of TGF-β/BMP/activin, not only in myostatin/ ActRIIB pathway ( Massague, Seoane & Wotton, 2005 ; Tian, Jiao & Cheng, 2018b ). Moreover, in the process of muscle protein balance, ActRIIB signal pathway stimulates FoxO -dependent transcription to enhance muscle protein catabolism and suppresses Akt / mTOR signaling to inhibit muscle protein synthesis ( Han et al, 2013 ; Hulmi et al, 2013 ; Tian et al, 2018 ; Tian, Lin & Jiao, 2019 ). Although the expression of mTOR was not influenced after dsRNA injection of Es-ActRIIB , the low expression of FoxO was observed, resulting in the slowed down protein catabolism that is needed to accelerate muscle protein synthesis.…”